

# EVA<sup>®</sup> 60 mg TABLET

## Composition

Each tablet contains :  
Raloxifene HCl 60 mg

## Indications and usage

EVA is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate .

Postmenopausal osteoporosis may be diagnosed by history or radiographic documentation of osteoporotic fracture, bone mineral densitometry, or physical signs of vertebral crush fractures.

## Contraindications

EVA is contraindicated in lactating women or women who are or may become pregnant. Eva may cause fetal harm when administered to a pregnant women.

EVA is contraindicated in women known to be hypersensitive to raloxifene or any other constituents of the tablets.

EVA is contraindicated in women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.

## Precautions

EVA should be discontinued at least 72 hours prior to and during prolonged immobilization. Patients should be advised to avoid prolonged restrictions of movement during travel because of the increased risk of venous thromboembolic events.

EVA may increase the incidence of hot flashes.

The modification of certain behavioral factors, such as cigarette smoking, and/ or alcohol consumption, should be considered.

## Dosage and Administration :

The recommended dosage is one 60-mg EVA tablet daily which may be administered any time of day without regard to meals.

## Presentation

Pack for 30 tablets

**PHARMADEX S.A.L.**  
KAHALE - LEBANON

